Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
BMRA's Cash-to-Debt is ranked higher than
99% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.28 vs. BMRA: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
BMRA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 4.42 Max: No Debt
Current: No Debt
0.04
No Debt
Equity-to-Asset 0.83
BMRA's Equity-to-Asset is ranked higher than
84% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. BMRA: 0.83 )
Ranked among companies with meaningful Equity-to-Asset only.
BMRA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.48 Max: 0.94
Current: 0.83
0.14
0.94
Interest Coverage No Debt
BMRA's Interest Coverage is ranked higher than
99% of the 162 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.70 vs. BMRA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
BMRA' s Interest Coverage Range Over the Past 10 Years
Min: 8.86  Med: 5257 Max: No Debt
Current: No Debt
8.86
No Debt
Piotroski F-Score: 4
Altman Z-Score: 23.37
Beneish M-Score: -3.07
WACC vs ROIC
-0.76%
-36.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -19.71
BMRA's Operating Margin % is ranked lower than
59% of the 238 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. BMRA: -19.71 )
Ranked among companies with meaningful Operating Margin % only.
BMRA' s Operating Margin % Range Over the Past 10 Years
Min: -19.71  Med: -4.94 Max: 10.33
Current: -19.71
-19.71
10.33
Net Margin % -18.74
BMRA's Net Margin % is ranked lower than
59% of the 238 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.33 vs. BMRA: -18.74 )
Ranked among companies with meaningful Net Margin % only.
BMRA' s Net Margin % Range Over the Past 10 Years
Min: -29.18  Med: -0.51 Max: 34.71
Current: -18.74
-29.18
34.71
ROE % -24.87
BMRA's ROE % is ranked lower than
60% of the 237 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. BMRA: -24.87 )
Ranked among companies with meaningful ROE % only.
BMRA' s ROE % Range Over the Past 10 Years
Min: -27.72  Med: 0.03 Max: 60.67
Current: -24.87
-27.72
60.67
ROA % -21.80
BMRA's ROA % is ranked lower than
61% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.74 vs. BMRA: -21.80 )
Ranked among companies with meaningful ROA % only.
BMRA' s ROA % Range Over the Past 10 Years
Min: -25.31  Med: -0.11 Max: 41.04
Current: -21.8
-25.31
41.04
ROC (Joel Greenblatt) % -40.56
BMRA's ROC (Joel Greenblatt) % is ranked lower than
56% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.40 vs. BMRA: -40.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BMRA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -40.56  Med: -3.35 Max: 116.88
Current: -40.56
-40.56
116.88
3-Year EBITDA Growth Rate 40.40
BMRA's 3-Year EBITDA Growth Rate is ranked higher than
85% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.50 vs. BMRA: 40.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BMRA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.1 Max: 110.5
Current: 40.4
0
110.5
3-Year EPS without NRI Growth Rate 54.20
BMRA's 3-Year EPS without NRI Growth Rate is ranked higher than
91% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. BMRA: 54.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BMRA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.9  Med: 0 Max: 122.4
Current: 54.2
-66.9
122.4
GuruFocus has detected 2 Warning Signs with Biomerica Inc BMRA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BMRA's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with BMRA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 8071
Compare:XCNQ:CHX, ASX:DVL, OTCPK:INIS, NAS:CODX, XPAR:ALBIO, HKSE:08247, LSE:COG, ROCO:6572, NGM:PRLD MTF, WAR:SNT, XKRX:109820, OSTO:MPI, TSXV:LXG, NAS:IDXG, XPAR:MLAHC, ASX:GTG, XKRX:238120, XKRX:214610, XKRX:246250, ROCO:1784 » details
Headquarter Location:USA
Biomerica Inc develops, manufactures, and markets medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions.

Biomerica Inc is part of the healthcare sector. The company develops medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. Biomerica's diagnostic test kits are used to analyze blood, urine or fecal specimens from patients in the diagnosis of various diseases and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which exist in the human body in various concentrations.

Top Ranked Articles about Biomerica Inc

Biomerica Announces Second Quarter Financial Results; Sales Up 12.7% for the Quarter
Biomerica Announces Second Quarter Financial Results; Sales Up 12.7% for the Quarter
China Food and Drug Administration (CFDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer
China Food and Drug Administration (CFDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer
Biomerica Signs Agreements with Beth Israel Deaconess & University of Michigan to Initiate Clinical Study for First of a Kind, Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy (DGT)
Biomerica Signs Agreements with Beth Israel Deaconess & University of Michigan to Initiate Clinical Study for First of a Kind, Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy (DGT)
Biomerica Extends Exclusive License Agreement with Celtis Pharm (Telcon Pharmaceuticals) to December 2019
Biomerica Reports 1st Quarter Fiscal 2018 Financials
Biomerica Commences Clinical Studies for New Gastroenterology H. Pylori Test
Biomerica Announces Fiscal Year End 2017 Financial Results; Sales Up 12.7% for the year

Ratios

vs
industry
vs
history
PB Ratio 9.83
BMRA's PB Ratio is ranked lower than
79% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. BMRA: 9.83 )
Ranked among companies with meaningful PB Ratio only.
BMRA' s PB Ratio Range Over the Past 10 Years
Min: 0.53  Med: 1.16 Max: 10.49
Current: 9.83
0.53
10.49
PS Ratio 6.56
BMRA's PS Ratio is ranked lower than
62% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.54 vs. BMRA: 6.56 )
Ranked among companies with meaningful PS Ratio only.
BMRA' s PS Ratio Range Over the Past 10 Years
Min: 0.45  Med: 1.16 Max: 7
Current: 6.56
0.45
7
EV-to-EBIT -33.90
BMRA's EV-to-EBIT is ranked lower than
99.99% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.76 vs. BMRA: -33.90 )
Ranked among companies with meaningful EV-to-EBIT only.
BMRA' s EV-to-EBIT Range Over the Past 10 Years
Min: -142.4  Med: -6.9 Max: 114.5
Current: -33.9
-142.4
114.5
EV-to-EBITDA -41.28
BMRA's EV-to-EBITDA is ranked lower than
99.99% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.87 vs. BMRA: -41.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
BMRA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.9  Med: -7.7 Max: 43.9
Current: -41.28
-43.9
43.9
EV-to-Revenue 6.47
BMRA's EV-to-Revenue is ranked lower than
57% of the 237 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.12 vs. BMRA: 6.47 )
Ranked among companies with meaningful EV-to-Revenue only.
BMRA' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 0.9 Max: 6.9
Current: 6.47
0.1
6.9
Current Ratio 5.10
BMRA's Current Ratio is ranked higher than
79% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. BMRA: 5.10 )
Ranked among companies with meaningful Current Ratio only.
BMRA' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 3.02 Max: 13
Current: 5.1
1
13
Quick Ratio 2.83
BMRA's Quick Ratio is ranked higher than
61% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. BMRA: 2.83 )
Ranked among companies with meaningful Quick Ratio only.
BMRA' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.76 Max: 8
Current: 2.83
0.47
8
Days Inventory 161.12
BMRA's Days Inventory is ranked lower than
79% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. BMRA: 161.12 )
Ranked among companies with meaningful Days Inventory only.
BMRA' s Days Inventory Range Over the Past 10 Years
Min: 153.04  Med: 194.91 Max: 231.62
Current: 161.12
153.04
231.62
Days Sales Outstanding 64.10
BMRA's Days Sales Outstanding is ranked higher than
52% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.41 vs. BMRA: 64.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMRA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.49  Med: 67.81 Max: 103.23
Current: 64.1
45.49
103.23
Days Payable 52.18
BMRA's Days Payable is ranked lower than
60% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 61.40 vs. BMRA: 52.18 )
Ranked among companies with meaningful Days Payable only.
BMRA' s Days Payable Range Over the Past 10 Years
Min: 26.61  Med: 35.5 Max: 52.18
Current: 52.18
26.61
52.18

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.10
BMRA's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -8.00 vs. BMRA: -4.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMRA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.6  Med: -3.4 Max: -1.1
Current: -4.1
-8.6
-1.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 92.80
BMRA's Price-to-Net-Cash is ranked lower than
99.99% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.82 vs. BMRA: 92.80 )
Ranked among companies with meaningful Price-to-Net-Cash only.
BMRA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 8.94 Max: 92.8
Current: 92.8
0
92.8
Price-to-Net-Current-Asset-Value 11.90
BMRA's Price-to-Net-Current-Asset-Value is ranked higher than
52% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.13 vs. BMRA: 11.90 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BMRA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.75  Med: 3.37 Max: 45
Current: 11.9
0.75
45
Price-to-Tangible-Book 10.09
BMRA's Price-to-Tangible-Book is ranked lower than
64% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.94 vs. BMRA: 10.09 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BMRA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.55  Med: 2.6 Max: 53.19
Current: 10.09
0.55
53.19
Price-to-Intrinsic-Value-Projected-FCF 464.00
BMRA's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
100% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. BMRA: 464.00 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BMRA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.65  Med: 2.46 Max: 464
Current: 464
0.65
464
Price-to-Median-PS-Value 5.66
BMRA's Price-to-Median-PS-Value is ranked lower than
98% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.95 vs. BMRA: 5.66 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BMRA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 0.7 Max: 5.66
Current: 5.66
0.04
5.66
Earnings Yield (Greenblatt) % -2.96
BMRA's Earnings Yield (Greenblatt) % is ranked lower than
56% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.04 vs. BMRA: -2.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BMRA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -20.5  Med: -3.8 Max: 94.9
Current: -2.96
-20.5
94.9
Forward Rate of Return (Yacktman) % 23.23
BMRA's Forward Rate of Return (Yacktman) % is ranked higher than
85% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.58 vs. BMRA: 23.23 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BMRA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -11.3  Med: -3.65 Max: 75.8
Current: 23.23
-11.3
75.8

More Statistics

Revenue (TTM) (Mil) $6.01
EPS (TTM) $ -0.13
Beta-0.61
Short Percentage of Float0.48%
52-Week Range $1.93 - 9.32
Shares Outstanding (Mil)8.54

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}